TORONTO, Oct. 21, 2021 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX: HLS), announces that it will release
its Q3 2021 financial results on Thursday,
November 4, 2021. The Company will hold a conference call
that same day at 8:30 a.m. EDT to
discuss its results. The call will be hosted by Mr. Gilbert Godin, Chief Executive Officer and Mr.
Tim Hendrickson, Chief Financial
Officer. Slides to accompany management's prepared remarks will
be available to view via the webcast.
|
CONFERENCE
ID:
|
97175749
|
|
|
|
DATE:
|
Thursday, November 4,
2021
|
|
|
|
TIME:
|
8:30 a.m.
EST
|
|
|
|
DIAL-IN
NUMBER:
|
1-888-664-6392 or
416-764-8659
|
|
|
|
WEBCAST LINK:
|
https://produceredition.webcasts.com/starthere.jsp?ei=1503335&tp_key=b9fb30d53b
|
|
|
|
TAPED
REPLAY:
|
1-888-390-0541 or
416-764-8677
|
|
|
|
REPLAY CODE:
|
175749
|
The taped replay will be available for 14 days and the archived
webcast will be available for 365 days.
A link to the live audio webcast of the conference call will
also be available on the events page of the investors section of
HLS Therapeutics' website at www.hlstherapeutics.com. Please
connect at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be required to
hear the webcast.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a
pharmaceutical company focused on the acquisition and
commercialization of late-stage development, commercial stage
promoted and established branded pharmaceutical products in the
North American markets. HLS's focus is on products targeting the
central nervous system and cardiovascular therapeutic areas. HLS's
management team is composed of seasoned pharmaceutical executives
with a strong track record of success in these therapeutic areas
and at managing products in each of these lifecycle stages. For
more information visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.